From professional translators, enterprises, web pages and freely available translation repositories.
cpmp/bpwg/2220/99
cpmp/ bpwg/ 282/ 00
Last Update: 2012-04-10
Usage Frequency: 3
Quality:
emea/cpmp/bpwg/575/99
emea/ cpmp/ bpwg/ 575/ 99
Last Update: 2012-04-10
Usage Frequency: 6
Quality:
statusemea/cpmp/bpwg/283/00
cpmp: n tehokkuustyöryhmä
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
emea/cpmp/bpwg/859/95 rev.
rev.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
reference number cpmp/bpwg/2220/99
viitenumero cpmp/bpwg/2220/99
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
blood and plasma working group (bpwg)
veri - ja plasmatyöryhmä (bpwg)
Last Update: 2012-04-10
Usage Frequency: 2
Quality:
cpmp/bpwg/3226/99 cpmp/bpwg/283/00
cpmp/bpwg/3226/99 cpmp/bpwg/283/00
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti-d immunoglobulin for intravenous and/or intramuscular use (cpmp/bpwg/574/99)
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti-d immunoglobulin for intravenous and/or intramuscular
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
